Melanotan I (10mg)

Melanotan I (10mg)

Current price is: $67.99. Original price was: $80.00.

Compound Melanotan I (10mg)
Category Melanocortin Agonists
Purity 99.553% (CoA Reported)
Form Lyophilised Powder
Storage (Lyophilised) -20 °C — protect from light & moisture
Storage (Reconstituted) 2–8 °C — use within 8–12 weeks

⚠ For in-vitro research and laboratory use only. Not intended for human or veterinary use. By purchasing, you confirm you are a qualified researcher and will use this compound in accordance with all applicable laws and regulations.

Melanotan I (10mg)

Current price is: $67.99. Original price was: $80.00.

Add to cart
Buy Now
SKU: PEP-026-10MG Category:

Selective MC1R Agonist (Afamelanotide)

Melanotan I (10mg) is supplied in Australia by Daza Enhanced with fast domestic shipping to all states and territories.

Melanotan I — also known as afamelanotide or MT1 — is a selective melanocortin-1 receptor (MC1R) agonist studied for melanin synthesis. Unlike Melanotan II (MT2), which is non-selective across MC1R/MC3R/MC4R/MC5R, MT1 acts primarily on MC1R and has a longer half-life. It is the same compound used in afamelanotide-based therapies clinically approved overseas for severe light-sensitivity conditions.

Key Research Areas

  • Melanogenesis — Stimulates melanin synthesis without UV exposure
  • Extended Half-Life — Significantly longer half-life than MT2, sustaining pigmentation studies over longer periods
  • Receptor Selectivity — Primarily MC1R-targeted; minimal MC3R/MC4R/MC5R activity
  • UV Photoprotection — Higher melanin levels studied for reduced UV-induced skin damage

Supplied as lyophilized powder at 99.553% purity as reported on the CoA, verified by HPLC and mass spectrometry. 10mg per vial. Fast domestic shipping across Australia, with batch-specific CoA information available in our CoA Library.

⚠ For in-vitro research and laboratory use only. Not for human consumption.

Reviews

There are no reviews yet.

Be the first to review “Melanotan I (10mg)”

Your email address will not be published. Required fields are marked *